08/09/2026 Vor Bio announced the completion of enrollment in its Phase 3 trial of telitacept in gMG Spyre Therapeutics announced Phase 2 Part A induction results for SPY003 in UC Alebund Pharmaceuticals announced FDA clearance of its IND application for AP308 for the treatment of IgA Nephropathy Greywolf Therapeutics dosed the first participant with axSpA in the Ph1/2 trial of GRWD0715. Vor Bio announced the completion of enrollment in its Phase 3 trial of telitacept in gMG.

29/06/2026 Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with Non-segmental Vitiligo Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with severe alopecia areata Zura Bio exceeded Phase 2 enrollment target for HS and SSc and expanded tibulizumab program Dianthus Therapeutics announced the initiation of a Phase 3 trial of claseprubart in gMG Abivax announced ABETACT maintenan

22/06/2026 Merck’s tulisokibart met primary and key secondary endpoints in a Phase 3 study in patiets with moderately to severely active UC FDA and EMA accepted cemdisiran regulatory submissions for review for the treatment of gMG Prolium Biosciences announced milestones in systemic sclerosis and refractory lupus nephritis Merck’s tulisokibart met primary and key secondary endpoints in a Phase 3 study in patiets with moderately to severely active UC (Ref) Merck announced posi

08/05/2026 BMS received EU approval of deucravacitinib for the treatment of active PsA in adults Argenx announced US approval expanding VYVGART and VYVGART Hytrulo for use in all adult patinets living with gMG BMS received EU approval of deucravacitinib for the treatment of active PsA in adults (Ref) BMS announced that the European Commission had granted approval to Sotyktu (deucravacitinib; TYK2 inhibitor), alone or in combination with methotrexate, for the treatment of acti

22/04/2026 Roche announced Phase 3 data for fenebrutinib in RMS Johnson & Johnson announced Phase 3 data for nipocalimab in gMG Sanofi's Tzield approved in the US to delay the onset of stage 3 T1D in young children Roche announced Phase 3 data for fenebrutinib in RMS (Ref) Roche announced new positive data from the Phase 3 FENhance 1 and 2 studies, Which investigated fenebrutinib (BTK inhibitor) for the treatment of patients with Relapsing Multiple Sclerosis (RMS). FENhance 1

12/02/2026 The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis ( Ref ) The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (M